eCite Digital Repository

Expert consensus for Multimodality Imaging Evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Citation

Plana, JC and Galderisi, M and Barac, A and Ewer, MS and Ky, B and Scherrer-Crosbie, M and Ganame, J and Sebag, IA and Agler, DA and Badano, LP and Banchs, J and Cardinale, D and Carver, J and Cerqueira, M and DeCara, JM and Edvardsen, T and Flamm, SD and Force, T and Griffin, BP and Jerusalem, G and Liu, JE and Magalhaes, A and Marwick, T and Sanchez, LY and Sicari, R and Villarraga, HR and Lancellotti, P, Expert consensus for Multimodality Imaging Evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Journal of the American Society of Echocardiography, 27, (9) pp. 911-939. ISSN 0894-7317 (2014) [Refereed Article]

Copyright Statement

Copyright 2014 by the American Society of Echocardiography

DOI: doi:10.1016/j.echo.2014.07.012

Abstract

Cardiac dysfunction resulting from exposure to cancer therapeutics was first recognized in the 1960s, with the widespread introduction of anthracyclines into the oncologic therapeutic armamentarium. Heart failure (HF) associated with anthracyclines was then recognized as an important side effect. As a result, physicians learned to limit their doses to avoid cardiac dysfunction. Several strategies have been used over the past decades to detect it. Two of them evolved over time to be very useful: endomyocardial biopsies and monitoring of left ven- tricular (LV) ejection fraction (LVEF) by cardiac imaging. Examination of endomyocardial biopsies proved to be the most sensitive and spe- cific parameter for the identification of anthracycline-induced LV dysfunction and became the gold standard in the 1970s. However, the interest in endomyocardial biopsy has diminished over time because of the reduction in the cumulative dosages used to treat ma- lignancies, the invasive nature of the procedure, and the remarkable progress made in noninvasive cardiac imaging. The noninvasive evaluation of LVEF has gained importance, and notwithstanding the limitations of the techniques used for its calculation, has emerged as the most widely used strategy for monitoring the changes in cardiac function, both during and after the administration of potentially car- diotoxic cancer treatment.

Item Details

Item Type:Refereed Article
Keywords:chemotherapy, Doxorubicin, Trastuzumab, left ventricular dysfunction, three-dimensional echocardiography, Early detection, Strain, Biomarkers
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Cardiology (incl. cardiovascular diseases)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Marwick, T (Professor Tom Marwick)
ID Code:94412
Year Published:2014
Web of Science® Times Cited:978
Deposited By:Menzies Institute for Medical Research
Deposited On:2014-09-09
Last Modified:2017-11-01
Downloads:0

Repository Staff Only: item control page